RayzeBio

RayzeBio, founded in 2020, is a cutting-edge player in the Biotechnology and Pharmaceutical sectors, focusing on the development of targeted innovative radiopharmaceuticals for cancer treatment. With a mission outlined in their slogan, "Targeted innovative radiopharmaceuticals for cancer," RayzeBio is dedicated to making transformative cancer therapies available to patients, aiming to revolutionize how cancers are treated.

Headquartered in the United States, RayzeBio recently achieved a significant milestone by being acquired for a $4.10B investment on 01 December 2023 by the global healthcare leader, Bristol-Myers Squibb. This acquisition underpins RayzeBio's compelling proposition and its potential to disrupt traditional cancer treatments with its innovative therapeutic solutions. As part of the Bristol Myers Squibb Company, RayzeBio is strategically positioned for accelerated clinical progress and wider patient access to its cutting-edge radiopharmaceutical therapies.